Identification

Name
Thiopental
Accession Number
DB00599  (APRD00660)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)

Structure
Thumb
Synonyms
  • (+-)-Thiopental
  • 2-Thio-5-ethyl-5-sec-pentylbarbituric acid
  • 5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione
  • Bitaryl
  • Omexolon
  • Penthiobarbital
  • Pentothiobarbital
  • Sodium Pentothal
  • Thiomebumalum
  • Thiopental
  • Thiopentobarbital
  • Thiopentobarbitone
  • Thiopentobarbituric acid
  • Thiopentone
  • Tiopentale
  • Trapanal
Product Ingredients
IngredientUNIICASInChI Key
Thiopental sodium49Y44QZL7071-73-8AWLILQARPMWUHA-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pentothal Inj 25mg/mlPowder, for solution25 mgIntravenousHospira, Inc.1988-12-31Not applicableCanada
Pentothal Inj 500mg/syrPowder, for solution500 mgIntravenousHospira, Inc.1986-12-31Not applicableCanada
Pentothal Ready To Mix Syringe 250mgPowder, for solution250 mgIntravenousHospira, Inc.1986-12-31Not applicableCanada
Pentothal Sodium Inj 1gm SterilePowder, for solution1 gIntravenousHospira, Inc.1951-12-31Not applicableCanada
Pentothal Sodium Pws 5gmPowder, for solution5 gIntravenousHospira, Inc.1975-12-31Not applicableCanada
International/Other Brands
Anestho (Incepta) / Bensulf (Fada ) / Bitol Sodium (Brookes) / Ekipental (Tüm Ekip) / Farmotal (Marvecs Pharma Services) / Intraval Sodium (Abbott) / Pental Sodyum (I.E. Ulagay) / Pentazol (Swiss Parenterals) / Penthal (Oboi) / Penthotal Sodium (Abbott) / Pentotan (Choong Wae) / Pentotex (Rotexmedica) / Pentothal (Hospira) / Ravonal (Ravonal) / Thiopen (ACI) / Tiopental (Richmond) / Trapanal (Nycomed)
Categories
UNII
JI8Z5M7NA3
CAS number
76-75-5
Weight
Average: 242.338
Monoisotopic: 242.10889852
Chemical Formula
C11H18N2O2S
InChI Key
IUJDSEJGGMCXSG-UHFFFAOYSA-N
InChI
InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
IUPAC Name
5-ethyl-5-(pentan-2-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
SMILES
CCCC(C)C1(CC)C(=O)NC(=S)NC1=O

Pharmacology

Indication

For use as the sole anesthetic agent for brief (15 minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders.

Structured Indications
Not Available
Pharmacodynamics

Thiopental, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Thiopental is an ultrashort-acting depressant of the central nervous system which induces hypnosis and anesthesia, but not analgesia. It produces hypnosis within 30 to 40 seconds of intravenous injection. Recovery after a small dose is rapid, with some somnolence and retrograde amnesia. Repeated intravenous doses lead to prolonged anesthesia because fatty tissues act as a reservoir; they accumulate Pentothal in concentrations 6 to 12 times greater than the plasma concentration, and then release the drug slowly to cause prolonged anesthesia

Mechanism of action

Thiopental binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
UNeuronal acetylcholine receptor subunit alpha-4
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-7
antagonist
Human
UGlutamate receptor 2
antagonist
Human
UGlutamate receptor ionotropic, kainate 2
antagonist
Human
UFatty-acid amide hydrolase 1
inhibitor
Human
UMuscarinic acetylcholine receptor M3Not AvailableHuman
Absorption

Rapidly absorbed.

Volume of distribution
Not Available
Protein binding

Approximately 80% of the drug in the blood is bound to plasma protein.

Metabolism

Primarily hepatic. Biotransformation products of thiopental are pharmacologically inactive and mostly excreted in the urine.

Route of elimination
Not Available
Half life

3-8 hours

Clearance
Not Available
Toxicity

Overdosage may occur from too rapid or repeated injections. Too rapid injection may be followed by an alarming fall in blood pressure even to shock levels. Apnea, occasional laryngospasm, coughing and other respiratory difficulties with excessive or too rapid injections may occur. Lethal blood levels may be as low as 1 mg/100 mL for short-acting barbiturates; less if other depressant drugs or alcohol are also present.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thiopental is combined with 7-Nitroindazole.Experimental
AcebutololThiopental may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Thiopental.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Thiopental.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Thiopental.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Thiopental.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Thiopental is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Thiopental is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Thiopental is combined with Alaproclate.Experimental
AldesleukinThiopental may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thiopental.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Thiopental.Approved, Vet Approved
AliskirenThiopental may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Thiopental is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Thiopental is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiopental.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Thiopental.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Thiopental.Experimental
AmifostineThiopental may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThiopental may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Thiopental.Illicit, Withdrawn
AminophyllineThe therapeutic efficacy of Thiopental can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThiopental may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Thiopental is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Thiopental.Approved
AmlodipineThiopental may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Thiopental.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Thiopental is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Thiopental is combined with Amperozide.Experimental
Amphotericin BThiopental may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Thiopental.Approved
Amyl NitriteThiopental may increase the hypotensive activities of Amyl Nitrite.Approved
ApomorphineThiopental may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineThiopental may increase the hypotensive activities of Apraclonidine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiopental.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Thiopental.Approved
Arsenic trioxideThiopental may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Thiopental.Approved
AtenololThiopental may increase the hypotensive activities of Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Thiopental is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Azaperone.Vet Approved
AzelastineThiopental may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Thiopental.Approved
Azilsartan medoxomilThiopental may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Thiopental.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Thiopental is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Barbital.Illicit
BarnidipineThe metabolism of Barnidipine can be increased when combined with Thiopental.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Thiopental.Experimental
BenazeprilThiopental may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe metabolism of Bencyclane can be increased when combined with Thiopental.Experimental
BendroflumethiazideThiopental may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Thiopental.Approved
BenperidolThe risk or severity of adverse effects can be increased when Thiopental is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thiopental is combined with Benzyl alcohol.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Thiopental.Approved, Withdrawn
BetaxololThiopental may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Thiopental.Approved
BisoprololThiopental may increase the hypotensive activities of Bisoprolol.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Thiopental.Investigational
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Thiopental.Approved
BortezomibThiopental may increase the hypotensive activities of Bortezomib.Approved, Investigational
BretyliumThiopental may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thiopental is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiopental.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Thiopental is combined with Bromisoval.Experimental
BromocriptineThiopental may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Thiopental is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Thiopental.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Thiopental.Experimental, Investigational
BumetanideThiopental may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiopental.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Thiopental.Approved
BuprenorphineThiopental may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiopental.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiopental.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Thiopental is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Thiopental is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiopental.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thiopental.Approved
CanagliflozinThiopental may increase the hypotensive activities of Canagliflozin.Approved
CandesartanThiopental may increase the hypotensive activities of Candesartan.Approved
CanertinibThe risk or severity of adverse effects can be increased when Thiopental is combined with Canertinib.Investigational
CaptoprilThiopental may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiopental.Approved, Investigational
CarbetocinThiopental may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be increased when combined with Thiopental.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Thiopental is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Thiopental is combined with Carisoprodol.Approved
CaroverineThe metabolism of Caroverine can be increased when combined with Thiopental.Experimental
CarteololThiopental may increase the hypotensive activities of Carteolol.Approved
CarvedilolThiopental may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Thiopental.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Thiopental.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Thiopental is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Thiopental can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiopental.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Chloroprocaine.Approved
ChlorothiazideThiopental may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Thiopental.Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorphenamine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Thiopental.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiopental.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThiopental may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorzoxazone.Approved
CilazaprilThiopental may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Thiopental.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiopental.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Thiopental.Approved
CitalopramThe risk or severity of adverse effects can be increased when Thiopental is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Thiopental is combined with Clemastine.Approved
ClevidipineThiopental may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Thiopental is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Thiopental is combined with Clobazam.Approved, Illicit
ClofarabineThiopental may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Thiopental is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Thiopental.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Thiopental is combined with Clopenthixol.Experimental
CloranololThe serum concentration of Cloranolol can be decreased when it is combined with Thiopental.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiopental.Approved, Illicit
ClorindioneThe metabolism of Clorindione can be increased when combined with Thiopental.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Thiopental is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiopental.Approved
CocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Thiopental.Approved, Illicit
ConivaptanThiopental may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated estrogensThe therapeutic efficacy of Conjugated estrogens can be decreased when used in combination with Thiopental.Approved
CyclizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Thiopental.Approved
CyclopenthiazideThiopental may increase the orthostatic hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Thiopental.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Thiopental is combined with Dantrolene.Approved
DapagliflozinThiopental may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiopental.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Thiopental.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Thiopental is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Thiopental.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Thiopental.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Thiopental.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Thiopental is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Thiopental is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Thiopental is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiopental.Approved, Illicit, Vet Approved
DiazoxideThiopental may increase the hypotensive activities of Diazoxide.Approved
DibenzepinThe metabolism of Dibenzepin can be increased when combined with Thiopental.Experimental
DiclofenamideThiopental may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Thiopental.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Thiopental.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Thiopental.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Thiopental is combined with Diethyl ether.Experimental
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Thiopental.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Thiopental is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiopental.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Thiopental.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Thiopental.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Thiopental.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiopental.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThiopental may increase the hypotensive activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Thiopental is combined with Dimenhydrinate.Approved
DinutuximabThiopental may increase the hypotensive activities of Dinutuximab.Approved
DiphenadioneThe metabolism of Diphenadione can be increased when combined with Thiopental.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiopental.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiopental.Approved, Illicit
DipyridamoleThiopental may increase the hypotensive activities of Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Thiopental is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Thiopental.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Thiopental.Investigational
DoxazosinThiopental may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Thiopental.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Thiopental.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Thiopental is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Thiopental.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Thiopental is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Thiopental.Approved
EcgonineThe risk or severity of adverse effects can be increased when Thiopental is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Thiopental is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Thiopental is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Thiopental.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Eltanolone.Investigational
EmpagliflozinThiopental may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilThiopental may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatThiopental may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Thiopental.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Thiopental is combined with Entacapone.Approved, Investigational
EpanololThe serum concentration of Epanolol can be decreased when it is combined with Thiopental.Experimental
EperisoneThe metabolism of Eperisone can be increased when combined with Thiopental.Approved, Investigational
EplerenoneThiopental may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolThiopental may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThiopental may increase the hypotensive activities of Eprosartan.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiopental.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thiopental.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Thiopental is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Thiopental.Investigational
EsmololThiopental may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Thiopental.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Thiopental.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Thiopental.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Thiopental.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Thiopental.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiopental.Approved
Etacrynic acidThiopental may increase the hypotensive activities of Etacrynic acid.Approved
EthanolThiopental may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiopental.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Thiopental.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiopental.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Thiopental.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Thiopental is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiopental.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Thiopental.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Thiopental is combined with Ezogabine.Approved
FelbamateThe serum concentration of Thiopental can be increased when it is combined with Felbamate.Approved
FelodipineThiopental may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Thiopental.Withdrawn
FenoldopamThiopental may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiopental.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Fexofenadine.Approved
FimasartanThiopental may increase the hypotensive activities of Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Thiopental is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Thiopental.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiopental.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiopental.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiopental.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Thiopental.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Thiopental.Approved, Investigational
FosinoprilThiopental may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Thiopental is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Thiopental is combined with Fospropofol.Approved, Illicit
FurosemideThiopental may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiopental.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Thiopental is combined with Gabapentin Enacarbil.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Thiopental.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Thiopental.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Thiopental is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Thiopental.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Thiopental is combined with Glutethimide.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Thiopental.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Thiopental is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiopental.Approved
HalothaneThe risk or severity of adverse effects can be increased when Thiopental is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Thiopental is combined with Heroin.Approved, Illicit
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Thiopental.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Hexobarbital.Approved
HydralazineThiopental may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideThiopental may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThiopental may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThiopental may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiopental.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Iloperidone.Approved
IloprostThiopental may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilThiopental may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Thiopental.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thiopental is combined with Indalpine.Investigational, Withdrawn
IndapamideThiopental may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Thiopental.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Thiopental is combined with Indiplon.Investigational
IndoraminThiopental may increase the hypotensive activities of Indoramin.Withdrawn
IprindoleThe metabolism of Iprindole can be increased when combined with Thiopental.Experimental
IrbesartanThiopental may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThiopental may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Thiopental.Approved, Vet Approved
Isosorbide DinitrateThiopental may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateThiopental may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineThiopental may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThiopental may increase the hypotensive activities of Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiopental.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Ketobemidone.Approved
LabetalolThiopental may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Thiopental.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Thiopental.Approved, Investigational
LandiololThe serum concentration of Landiolol can be decreased when it is combined with Thiopental.Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Thiopental.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Thiopental is combined with Levetiracetam.Approved, Investigational
LevobunololThiopental may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Thiopental is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Thiopental is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Thiopental is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Thiopental is combined with Levomilnacipran.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Thiopental.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiopental.Approved
LevosimendanThiopental may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Thiopental.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be increased when combined with Thiopental.Experimental
LisinoprilThiopental may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Thiopental.Approved
LithiumThe risk or severity of adverse effects can be increased when Thiopental is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Thiopental is combined with Lofentanil.Illicit
LofepramineThe metabolism of Lofepramine can be increased when combined with Thiopental.Experimental
LofexidineThiopental may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiopental.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Lormetazepam.Approved
LosartanThiopental may increase the hypotensive activities of Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Thiopental.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiopental.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Thiopental.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Thiopental.Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Thiopental.Illicit, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Thiopental.Approved
MannitolThiopental may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Thiopental is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Thiopental is combined with Mebicar.Experimental
MecamylamineThiopental may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Thiopental.Approved, Investigational
MefloquineThe therapeutic efficacy of Thiopental can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Thiopental is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Melperone.Approved
MepindololThe serum concentration of Mepindolol can be decreased when it is combined with Thiopental.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiopental.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Thiopental is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiopental.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Thiopental.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Thiopental.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Thiopental.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Thiopental is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Thiopental.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Thiopental is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThiopental may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Thiopental is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiopental.Approved
MethotrimeprazineThiopental may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Thiopental is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Thiopental is combined with Methsuximide.Approved
MethyclothiazideThiopental may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaThiopental may increase the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Thiopental is combined with Methylecgonine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Thiopental.Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Thiopental.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Thiopental.Approved
MetipranololThiopental may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThiopental may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololThiopental may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineThiopental may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Thiopental.Experimental
MianserinThe therapeutic efficacy of Thiopental can be decreased when used in combination with Mianserin.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Thiopental.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiopental.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Thiopental is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Investigational
MinoxidilThiopental may increase the hypotensive activities of Minoxidil.Approved
MirtazapineThiopental may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoexiprilThiopental may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Thiopental.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thiopental.Approved, Investigational
MoxonidineThiopental may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Investigational
NadololThiopental may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Thiopental.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiopental.Approved
NebivololThiopental may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Nefazodone.Approved, Withdrawn
NesiritideThiopental may increase the hypotensive activities of Nesiritide.Approved, Investigational
NicardipineThiopental may increase the hypotensive activities of Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Thiopental.Approved
NifedipineThiopental may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Thiopental.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Thiopental.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Thiopental.Approved
NimesulideThe metabolism of Nimesulide can be increased when combined with Thiopental.Approved, Withdrawn
NimodipineThiopental may increase the hypotensive activities of Nimodipine.Approved
NisoldipineThiopental may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiopental.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Thiopental.Approved
Nitric OxideThiopental may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinThiopental may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideThiopental may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Thiopental.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Thiopental.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Thiopental is combined with Norflurane.Investigational
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Thiopental.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Thiopental.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Thiopental.Approved
ObinutuzumabThiopental may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiopental.Approved, Investigational
OlmesartanThiopental may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Thiopental is combined with Ondansetron.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Thiopental.Investigational
OpiumThe risk or severity of adverse effects can be increased when Thiopental is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Thiopental can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineThiopental may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Thiopental is combined with Osanetant.Investigational
OtiloniumThe metabolism of Otilonium can be increased when combined with Thiopental.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiopental.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiopental.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thiopental.Approved, Investigational, Vet Approved
PaclitaxelThiopental may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Thiopental.Approved
PapaverineThiopental may increase the hypotensive activities of Papaverine.Approved
ParaldehydeThiopental may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Paroxetine.Approved, Investigational
PenbutololThiopental may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Thiopental is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiopental.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiopental.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Thiopental.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Thiopental.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be increased when combined with Thiopental.Approved
PerindoprilThiopental may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Thiopental is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiopental.Approved
PethidineThiopental may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenazocine.Experimental
PhenelzineThiopental may increase the hypotensive activities of Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenibut.Experimental
PhenindioneThe metabolism of Phenindione can be increased when combined with Thiopental.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiopental.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenoperidine.Experimental
PhenoxybenzamineThiopental may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Thiopental.Approved
PhentolamineThiopental may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Thiopental.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Thiopental.Approved
PindololThiopental may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Thiopental is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Thiopental is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Thiopental.Approved
PizotifenThe risk or severity of adverse effects can be increased when Thiopental is combined with Pizotifen.Approved
PolythiazideThiopental may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Thiopental is combined with Pomalidomide.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Thiopental.Approved
PramipexoleThiopental may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Thiopental.Approved
PrazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Prazepam.Approved, Illicit
PrazosinThiopental may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiopental.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Thiopental.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Thiopental.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopental.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Thiopental.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Thiopental.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Thiopental.Approved
PropanididThe risk or severity of adverse effects can be increased when Thiopental is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Proparacaine.Approved, Vet Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Thiopental.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Thiopental.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Propoxycaine.Approved
PropranololThiopental may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Thiopental.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Thiopental is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Thiopental is combined with PSD502.Investigational
PyridoxineThe metabolism of Thiopental can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Thiopental.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiopental.Approved
QuinaprilThiopental may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThiopental may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Thiopental is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Thiopental is combined with Ramelteon.Approved, Investigational
RamiprilThiopental may increase the hypotensive activities of Ramipril.Approved
RasagilineThiopental may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiopental.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiopental.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiopental.Approved
RifabutinThe metabolism of Thiopental can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Thiopental can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Thiopental can be increased when combined with Rifapentine.Approved
RiociguatThiopental may increase the hypotensive activities of Riociguat.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Thiopental.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiopental.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Thiopental is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Romifidine.Vet Approved
RopiniroleThiopental may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiopental.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Thiopental.Approved
RotigotineThiopental may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thiopental.Approved
SacubitrilThiopental may increase the hypotensive activities of Sacubitril.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiopental.Approved, Vet Approved
SelegilineThiopental may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Thiopental is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Thiopental is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiopental.Approved, Vet Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Thiopental.Approved
Sodium NitriteThiopental may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Thiopental.Approved
SotalolThiopental may increase the hypotensive activities of Sotalol.Approved
SpironolactoneThiopental may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Thiopental is combined with Stiripentol.Approved
StreptokinaseThiopental may increase the hypotensive activities of Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiopental.Approved, Investigational
SulfisoxazoleThe therapeutic efficacy of Thiopental can be increased when used in combination with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiopental.Approved
SultoprideThe risk or severity of adverse effects can be increased when Thiopental is combined with Sultopride.Experimental
SuvorexantThiopental may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Thiopental.Approved
TalinololThe serum concentration of Talinolol can be decreased when it is combined with Thiopental.Investigational
TamsulosinThiopental may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Thiopental is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Thiopental is combined with Tasimelteon.Approved
TelmisartanThiopental may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiopental.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Thiopental.Approved
TerazosinThiopental may increase the hypotensive activities of Terazosin.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Thiopental.Experimental
TerodilineThe metabolism of Terodiline can be increased when combined with Thiopental.Experimental
TertatololThe serum concentration of Tertatolol can be decreased when it is combined with Thiopental.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrodotoxin.Investigational
ThalidomideThiopental may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Thiopental.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiopental is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Thiopental.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Thiopental.Withdrawn
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiopental.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Thiopental.Approved
TiagabineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tiagabine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Thiopental.Approved
TiaprideThe risk or severity of adverse effects can be increased when Thiopental is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tilidine.Experimental
TimololThiopental may increase the hypotensive activities of Timolol.Approved
TioclomarolThe metabolism of Tioclomarol can be increased when combined with Thiopental.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tizanidine.Approved
TolazolineThiopental may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Thiopental is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Thiopental.Approved
TopiramateThe risk or severity of adverse effects can be increased when Thiopental is combined with Topiramate.Approved
TorasemideThiopental may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiopental.Approved, Investigational
TrandolaprilThiopental may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Thiopental.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Trazodone.Approved, Investigational
TretinoinThiopental may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThiopental may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiopental.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Thiopental is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThiopental may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Thiopental is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiopental.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Thiopental is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiopental.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Thiopental.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Triprolidine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Thiopental.Experimental
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Thiopental.Approved
Valproic AcidThe serum concentration of Thiopental can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThiopental may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Thiopental is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Thiopental is combined with Veralipride.Experimental
VerapamilThiopental may increase the hypotensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Thiopental is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Thiopental.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Thiopental is combined with Vinyl ether.Experimental
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Thiopental.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Thiopental.Approved
XenonThe risk or severity of adverse effects can be increased when Thiopental is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Thiopental is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Thiopental.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiopental.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Thiopental is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiopental.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Zolazepam.Vet Approved
ZolpidemThiopental may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Thiopental is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Thiopental.Approved
ZotepineThe risk or severity of adverse effects can be increased when Thiopental is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Thiopental.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Morgan DJ, Blackman GL, Paull JD, Wolf LJ: Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. Anesthesiology. 1981 Jun;54(6):474-80. [PubMed:7235275]
  2. Perez-Barcena J, Barcelo B, Homar J, Abadal JM, Molina FJ, de la Pena A, Sahuquillo J, Ibanez J: [Comparison of the effectiveness of pentobarbital and thiopental in patients with refractory intracranial hypertension. Preliminary report of 20 patients]. Neurocirugia (Astur). 2005 Feb;16(1):5-12; discussion 12-3. [PubMed:15756405]
  3. WINTERS WD, SPECTOR E, WALLACH DP, SHIDEMAN FE: Metabolism of thiopental-S35 and thiopental-2-C14 by a rat liver mince and identification of pentobarbital as a major metabolite. J Pharmacol Exp Ther. 1955 Jul;114(3):343-57. [PubMed:13243246]
  4. Bory C, Chantin C, Boulieu R, Cotte J, Berthier JC, Fraisse D, Bobenrieth MJ: [Use of thiopental in man. Determination of this drug and its metabolites in plasma and urine by liquid phase chromatography and mass spectrometry]. C R Acad Sci III. 1986;303(1):7-12. [PubMed:3093002]
External Links
Human Metabolome Database
HMDB14737
KEGG Compound
C07521
PubChem Compound
3000715
PubChem Substance
46504621
ChemSpider
2272258
BindingDB
50058058
ChEBI
102166
ChEMBL
CHEMBL441
Therapeutic Targets Database
DAP000661
PharmGKB
PA451664
IUPHAR
2579
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Thiopental
ATC Codes
N05CA19 — ThiopentalN01AF03 — ThiopentalN05CB01 — Combinations of barbiturates

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAmnesia-Memory Loss / Memory Losses1
1, 2Unknown StatusTreatmentComplications1
2CompletedPreventionStrabismus1
3RecruitingTreatmentShock, Septic1
3TerminatedTreatmentTraumatic Brain Injury (TBI)1
3TerminatedTreatmentRefractory seizure disorders1
4CompletedTreatmentAgeing / Induction of Anaesthesia1
4CompletedTreatmentCoronary Artery Disease / Valvular Heart Disease1
4CompletedTreatmentSubfertility1
4Unknown StatusNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableAnxiety, Preoperative / Cesarean Section / Maternal Hypotension / Sedation therapy / Spinal Anaesthesia1
Not AvailableCompletedHealth Services ResearchAlcoholism1
Not AvailableCompletedTreatmentAdverse Effect of Other General Anesthetics1
Not AvailableRecruitingTreatmentAnoxic Encephalopathy / Cardiac Arrest / Refractory seizure disorders1
Not AvailableUnknown StatusBasic SciencePhobic Disorders1

Pharmacoeconomics

Manufacturers
  • Abbott laboratories hosp products div
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous25 mg
Powder, for solutionIntravenous500 mg
Powder, for solutionIntravenous250 mg
Powder, for solutionIntravenous1 g
Powder, for solutionIntravenous5 g
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.85HANSCH,C ET AL. (1995)
logS-3.36ADME Research, USCD
pKa7.55SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0398 mg/mLALOGPS
logP3.05ALOGPS
logP2.78ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)7.2ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity65.99 m3·mol-1ChemAxon
Polarizability25.7 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5106
Blood Brain Barrier+0.9505
Caco-2 permeable-0.5463
P-glycoprotein substrateNon-substrate0.5623
P-glycoprotein inhibitor INon-inhibitor0.5373
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.9031
CYP450 2C9 substrateNon-substrate0.8052
CYP450 2D6 substrateNon-substrate0.858
CYP450 3A4 substrateNon-substrate0.6688
CYP450 1A2 substrateNon-inhibitor0.8297
CYP450 2C9 inhibitorNon-inhibitor0.5588
CYP450 2D6 inhibitorNon-inhibitor0.914
CYP450 2C19 inhibitorNon-inhibitor0.5927
CYP450 3A4 inhibitorNon-inhibitor0.8813
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8482
Ames testNon AMES toxic0.6907
CarcinogenicityNon-carcinogens0.8992
BiodegradationNot ready biodegradable0.9917
Rat acute toxicity2.7671 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9827
hERG inhibition (predictor II)Non-inhibitor0.6314
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.6 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0596-9600000000-1b2c7562818b87a3dce1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0900000000-2256e1984e122af286e5
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0090000000-c8a2b96397abdac51af0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-4090000000-3397f51adf5ac5e26757
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-9010000000-2049e423160775847315
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-9000000000-e858eafc5134f3cf550e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-9000000000-aed0d4351672086bb8bf
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-9000000000-aed0d4351672086bb8bf
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0090000000-0da49458314b6213fc56
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-4090000000-5e98b0adc2fa68ac83f3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-9000000000-35496d92c575e3289c20
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-9000000000-aed0d4351672086bb8bf
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-9000000000-e858eafc5134f3cf550e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-9000000000-e858eafc5134f3cf550e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0900000000-2f4595765496ded39eec

Taxonomy

Description
This compound belongs to the class of organic compounds known as thiobarbituric acid derivatives. These are organic compounds containing a 2-thioxodihydropyrimidine-4,6(1H,5H)-dione skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Thiobarbituric acid derivatives
Alternative Parents
Diazinanes / Thioureas / Carboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Thiobarbiturate / 1,3-diazinane / Thiourea / Azacycle / Carboxylic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
barbiturates (CHEBI:102166)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
  5. Grasshoff C, Netzhammer N, Schweizer J, Antkowiak B, Hentschke H: Depression of spinal network activity by thiopental: shift from phasic to tonic GABA(A) receptor-mediated inhibition. Neuropharmacology. 2008 Oct;55(5):793-802. doi: 10.1016/j.neuropharm.2008.06.026. Epub 2008 Jun 21. [PubMed:18619475]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ionotropic glutamate receptor activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA2
Uniprot ID
P42262
Uniprot Name
Glutamate receptor 2
Molecular Weight
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Kainate selective glutamate receptor activity
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIK2
Uniprot ID
Q13002
Uniprot Name
Glutamate receptor ionotropic, kainate 2
Molecular Weight
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Fatty acid amide hydrolase activity
Specific Function
Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of t...
Gene Name
FAAH
Uniprot ID
O00519
Uniprot Name
Fatty-acid amide hydrolase 1
Molecular Weight
63065.28 Da
References
  1. Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, Falck JR, Nithipatikom K, Campbell WB, Hillard CJ: The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13. [PubMed:12839875]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Hirota K, Hashimoto Y, Lambert DG: Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. Anesth Analg. 2002 Dec;95(6):1607-10, table of contents. [PubMed:12456425]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:40